Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran

Lancet

Volumn 351, Issue 9115, 1998, Pages 1540-1543

  Sharifi, Iraj ^a   Fekri, Ali Reza ^a   Aflatonian, Mohammad Reza ^b   Khamesipour, Ali ^c   Nadim, Abolhassan ^d   Ahmadi Mousavi, Mohammad Reza ^a   Momeni, Ali Z ^e   Dowlati, Yahya ^c   Godal, Tore ^f   Zicker, Fabio ^f   Smith, Peter G ^g   Modabber, Farrokh ^f,h  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Provincial Health Centre   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f WORLD BANK   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; LEISHMANIA VACCINE;

ADOLESCENT; ADVERSE DRUG REACTION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; IRAN; LEISHMANIA MAJOR; MALE; MORBIDITY; NORMAL HUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN LEISHMANIASIS; SKIN TEST; VACCINATION;

EID: 7144254432     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)09552-X     Document Type: Article

References (19)

1. 1 Desjeux P. Cutaneous leishmaniasis: clinical aspects. In: Dowlati Y, Modabber F, eds. Clinics in dermatology. New York: Elsevier, 1996: 417-23.
2. 2 Nadim A. Current situation with regard to leishmaniasis in the countries of the eastern Mediterranean Region - an overview. In: Walton BC, Wijeyaratne PM, Modabber F, eds. Research on control strategies for leishmaniasis. Ottawa: IDRC, 1988: 162-67d.
3. 3 Nadim A, Javadian E. Leishmanization in the Islamic Republic of Iran. In: Walton BC, Wijeyaratne PM, Modabber F, eds. Research on control strategies for leishmaniasis. Ottawa: IDRC, 1988: 336-39.
4. 4 Modabber F. Vaccine: the only hope to control leishmaniasis. In: Tapia J, Caceres-Dittmar G, Sanchez MA, eds. Molecular and immune mechanisms in the pathogenesis of cutaneous leishmaniasis. R G Landes Co, 1996: 23-36.
5. 5 Mayrink W, da Costa CA, Magalhaes PA, et al. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 1979; 73: 385-87.
6. 6 Mayrink W, Williams P, da Costa CA, et al. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil. Ann Trop Med Parasitol 1985; 79: 259-69.
7. 7 Antunes CMF, Mayrink W, Magalhaes PA, et al. Controlled field trials of a vaccine against new world cutaneous leishmaniasis. Int J Epidemiol 1986; 15: 572-80.
8. 8 Convit J, Casttellanos PL, Rondon A, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987; 1: 401-05.
9. 9 Convit J, Castellanos PL, Ulrich M, et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis 1989; 160: 104-15.
10. 10 Mohebali M, Javadian EH, Hashemi-Fesharki R, et al. Trial of a non-living crude vaccine against zoonotic cutaneous leishmaniasis. Med J Islamic Rep Iran 1995; 8: 211-15.
11. 11 Bahar K, Dowlati Y, Shidani B, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. In: Dowlati Y, Modabber F, eds. Clinics in dermatology. New York: Elsevier, 1996; 14: 489-95.
12. 12 Alimohammadian MH, Hakimi H, Nikseresht M. The preparation and evaluation of reference leishmanin from Leishmania major for use in man for diagnostic and experimental purposes. Med J Islam Rep Iran 1993; 7: 23-18.
13. 13 Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975; 293: 501-02.
14. 14 Hashemi-Fesharki R, Alle-Agha S, Ahourai P, et al. Vaccine preparation and quality control of killed Leishmania major. Arch Inst Razi 1992; 43: 39-50.
15. 15 Evans DA. Leishmania. In: Taylor AER, Baker JR, eds. In-vitro methods for parasite cultivation. London: Academic Press, 1987: 52-57.
16. 16 Weintraub J, Weinbaum FI. The effect of BCG on experimental cutaneous leishmaniasis in mice. J Immunol 1977; 118: 2288-90.
17. 17 Smrkovski LL, Larson CL. Antigenic cross-reactivity between Mycobacterium bovis (BCG) and Leishmania donovani. Infect Immun 1977; 18: 561-62.
18. 18 Stefani MM, Muller I, Louis J. Leishmania major in BALB/C mice: protection or exacerbation by treatment with different doses of BCG? Res Immunol 1993; 144: 233-43.
19. 19 Abbas AL, Murphy KM, Sher A. Functional diversity of helper T Lymphocytes. Nature 1996; 383: 787-93.